Athira Pharma Future Growth
Future criteria checks 0/6
Athira Pharma is forecast to grow earnings at 25.9% per annum. EPS is expected to grow by 30.2% per annum.
Key information
25.9%
Earnings growth rate
30.2%
EPS growth rate
| Pharmaceuticals earnings growth | 24.0% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 11 Dec 2024 |
Recent future growth updates
Recent updates
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?
Feb 16
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
Nov 02Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
May 29Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Jan 04Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis
Oct 17Athira Pharma GAAP EPS of -$0.65
Aug 15We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Aug 09Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
Jun 22Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth
May 08We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
Jan 11Athira Pharma: What, Exactly, Did The CEO Do?
Jun 29Athira Pharma falls after the decision to place CEO on temporary leave
Jun 17Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy
Jun 07We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth
May 24We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Feb 08
Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
Jan 11Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like
Dec 18Athira Pharma nabs research grant of $15M from NIH
Dec 08Athira Pharma reports Q3 results
Nov 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -33 | -149 | N/A | 2 |
| 12/31/2025 | N/A | -58 | -132 | N/A | 3 |
| 12/31/2024 | N/A | -98 | -96 | N/A | 4 |
| 9/30/2024 | N/A | -109 | -97 | -97 | N/A |
| 6/30/2024 | N/A | -113 | -98 | -98 | N/A |
| 3/31/2024 | N/A | -116 | -100 | -100 | N/A |
| 12/31/2023 | N/A | -118 | -101 | -101 | N/A |
| 9/30/2023 | N/A | -121 | -90 | -90 | N/A |
| 6/30/2023 | N/A | -108 | -88 | -88 | N/A |
| 3/31/2023 | N/A | -102 | -83 | -82 | N/A |
| 12/31/2022 | N/A | -96 | -74 | -72 | N/A |
| 9/30/2022 | N/A | -82 | -77 | -75 | N/A |
| 6/30/2022 | N/A | -77 | -66 | -64 | N/A |
| 3/31/2022 | N/A | -67 | -54 | -52 | N/A |
| 12/31/2021 | N/A | -55 | -45 | -43 | N/A |
| 9/30/2021 | N/A | -46 | -38 | -36 | N/A |
| 6/30/2021 | N/A | -39 | -37 | -35 | N/A |
| 3/31/2021 | N/A | -27 | -33 | -30 | N/A |
| 12/31/2020 | N/A | -20 | -26 | -24 | N/A |
| 9/30/2020 | N/A | -13 | -15 | -14 | N/A |
| 6/30/2020 | N/A | -6 | -6 | -6 | N/A |
| 3/31/2020 | N/A | -6 | -4 | -4 | N/A |
| 12/31/2019 | N/A | -5 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATHA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATHA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATHA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ATHA's revenue is forecast to grow faster than the US market.
High Growth Revenue: ATHA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATHA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 08:36 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Athira Pharma, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| Thomas Shrader | BTIG |
| Corinne Johnson | Goldman Sachs |